National Hospital Organization Nagara Medical Center

Sendero Health Plans Names Sharon Alvis as Next Chief Executive

Retrieved on: 
Thursday, September 21, 2023
Insurance, EAP, Health, Central Health, Saint David, PHO, PPO, Central Health (Texas), HMO, Preferred provider organization, Health maintenance organization, Organization, Medicare, Hospital, Affordable Care Act, Hugh Delargy, ACA, Physician, National Hospital Organization Nagara Medical Center, Provisions of the Affordable Care Act, Alvis, St Davids, Health insurance marketplace, Curative, Health insurance, Retail, Central Texas

AUSTIN, Texas, Sept. 21, 2023 /PRNewswire/ -- Sendero Health Plans Inc. (Sendero) announced Wednesday it has named Sharon J. Alvis as the new chief executive officer to lead the nonprofit health maintenance organization (HMO), which was created and is funded and owned by Central Health.

Key Points: 
  • AUSTIN, Texas, Sept. 21, 2023 /PRNewswire/ -- Sendero Health Plans Inc. (Sendero) announced Wednesday it has named Sharon J. Alvis as the new chief executive officer to lead the nonprofit health maintenance organization (HMO), which was created and is funded and owned by Central Health.
  • Sendero offers health insurance plans through the Affordable Care Act's (ACA) federal Health Insurance Marketplace.
  • I have closely followed the evolution and experience of Sendero Health Plans from its inception and was excited about the potential to directly contribute."
  • Alvis continued, "With its unique structure and ownership, Sendero, in collaboration with the Central Health System, has a unique opportunity to maximize powerful collective resources.

Children's National Hospital Announces Partnership With Clearway Health

Retrieved on: 
Monday, October 3, 2022
Bed, Pharmacy, Hospital, Volunteering, Time, Research, Maria Sklodowska-Curie National Research Institute of Oncology, Children's National Hospital, Civil War, Health, National Hospital Organization Nagara Medical Center, Doctor of Pharmacy, Family, National, Education, CNH, Boston Medical Center, Partnership, National Research Corporation, Pharmacist, Human, Program, Patient, Harwell Science and Innovation Campus, GLOBE, Medicine

Clearway Health has redefined partnership and demonstrated that they will support our patients as an extension of CNH into the communities we serve."

Key Points: 
  • Clearway Health has redefined partnership and demonstrated that they will support our patients as an extension of CNH into the communities we serve."
  • "Children's National Hospital exemplifies its core values - compassion, commitment and connection - in the care they provide to their patients," said Nicole Faucher, President of Clearway Health.
  • "Our partnership with Clearway Health allows us to strengthen our commitment and focus on what's right, not just what's required, for our patients."
  • Now, Clearway Health serves hospitals, health systems and the communities of patients they care for - providing a service that's been proven, lived and experienced by our team.

Atamyo Therapeutics Announces First Patient Dosed with ATA-100 Gene Therapy in LGMD-R9 Clinical Trial

Retrieved on: 
Monday, September 26, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Safety, Trial of the century, FR, EudraCT, UMR, AAV, Food, European Medicines Agency, Weakness, Hope, Muscular dystrophy, National Hospital Organization Nagara Medical Center, Lists of diseases, Life, Therapy, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, FKRP, LGMD, Degenerative disease, Rigshospitalet, Research, Motivation, Pharmaceutical industry, Vaccine

John Vissing, Director of the Copenhagen Neuromuscular Center at the National Hospital, Rigshospitalet, in Copenhagen, where the first patient was dosed, and principal investigator of this trial.

Key Points: 
  • John Vissing, Director of the Copenhagen Neuromuscular Center at the National Hospital, Rigshospitalet, in Copenhagen, where the first patient was dosed, and principal investigator of this trial.
  • Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
  • A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.
  • Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

The First 1,000 Days: A Window of Opportunity for a Brighter Future for Children

Retrieved on: 
Friday, September 23, 2022
Health, Essay, Pediatrics, Center, Child, Department, Policy, Editorial, Infant, National Hospital Organization Nagara Medical Center, Population, Industry, Pregnancy, Postpartum period, United States Department of Health and Human Services, Work, Solution, Science, Collection, Research, Children's National Hospital, Mortality, Centers for Disease Control and Prevention timeline, Communication, American Journal of Public Health, Public health, AJPH, Mother, Birth control

WASHINGTON, Sept. 23, 2022 /PRNewswire/ -- The infant and maternal mortality rates in the US are among the highest of any wealthy country, with glaring racial and ethnic disparities. There is significant room to develop a unifying plan for the right policies and systems to improve nutritional security and well-being for vulnerable families. As part of a special series, sponsored by 1,000 Days of FHI Solutions, that will appear in American Journal of Public Health (AJPH) on October 26, 2022. The full series will present the state of science, research needs, and a policy agenda for optimal maternal and child nutrition in the US.

Key Points: 
  • There is significant room to develop a unifying plan for the right policies and systems to improve nutritional security and well-being for vulnerable families.
  • As part of a special series, sponsored by 1,000 Days of FHI Solutions, that will appear in American Journal of Public Health (AJPH) on October 26, 2022.
  • The full series will present the state of science, research needs, and a policy agenda for optimal maternal and child nutrition in the US.
  • Thus, this journal series brings together papers on these topics during pregnancy, birth, the postpartum period, and early childhood for the US population.

Atamyo Therapeutics Obtains First Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9

Retrieved on: 
Monday, December 6, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, Patient, Weakness, Muscular dystrophy, CEO, Degenerative disease, Biomarker, Health care, MHRA, CTAS, LGMD, Research, CNRS, Motivation, AAV, FKRP, CTA, Therapy, National Hospital Organization Nagara Medical Center, Lists of diseases, Life, Pathology, Newcastle University, Pharmaceutical industry, Dentistry

Atamyo plans to initiate dosing in patients for ATA-100 in the first half of 2022.

Key Points: 
  • Atamyo plans to initiate dosing in patients for ATA-100 in the first half of 2022.
  • ATA-100, a gene therapy candidate for LGMD21/R9, delivers a normal copy of the gene for production of FKRP proteins.
  • Atamyo Therapeutics is focused on the development of a new generation of effective and safe gene therapies for neuromuscular diseases.
  • A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon.